Scope Fluidics Spolka AkcyjnaWAR:SCP -0.49%50 Net Current Asset Value is zł37.22 as of Mar. 2026, which is 100% below its 10-year median of 6.04. GuruFocus rates WAR:SCP with a GF Score™ of 50/100 and a GF Value™ of zł129.17 (Fairly Valued). The stock has 4 warning signs investors should review. Among 100 Medical Diagnostics & Research companies, Scope Fluidics Spolka Akcyjna ranks better than 58% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Scope Fluidics Spolka Akcyjna's net current asset value per share for the quarter that ended in Mar. 2026 was zł37.22.
The historical rank and industry rank for Scope Fluidics Spolka Akcyjna's Net Current Asset Value or its related term are showing as below:
WAR:SCP'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.52 Med: 6.04 Max: 181.25
Current: 3.28
During the past 10 years, the highest Price-to-Net-Current-Asset-Value Ratio of Scope Fluidics Spolka Akcyjna was 181.25. The lowest was 1.52. And the median was 6.04.
WAR:SCP's Price-to-Net-Current-Asset-Value is ranked better than 58% of 100
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.03
vs WAR:SCP: 3.28
Scope Fluidics Spolka Akcyjna (WAR:SCP) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Scope Fluidics Spolka Akcyjna Net Current Asset Value Related Terms
Scope Fluidics Spolka Akcyjna Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scope Fluidics Spolka Akcyjna Net Current Asset Value Chart
WAR:SCP vs TMO, DHR, IDXX: Net Current Asset Value Comparison
For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scope Fluidics Spolka Akcyjna Price-to-Net-Current-Asset-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Scope Fluidics Spolka Akcyjna's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of zł37.22 mean?
Scope Fluidics Spolka Akcyjna (WAR:SCP) has a Net Current Asset Value of zł37.22 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. This is 516% above median its historical median of 6.04. Over the past decade, Scope Fluidics Spolka Akcyjna's Net Current Asset Value has ranged from 1.52 to 181.25. According to the industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #42 out of 100 companies in the Medical Diagnostics & Research industry, placing it in the top 42%.
Is Scope Fluidics Spolka Akcyjna's Net Current Asset Value too high?
Scope Fluidics Spolka Akcyjna's current Net Current Asset Value of zł37.22 is 516% above median its 10-year median of 6.04. Over the past 10 years, this metric has ranged from a low of 1.52 to a high of 181.25. Based on the distribution chart, Scope Fluidics Spolka Akcyjna ranks #42 out of 100 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's Net Current Asset Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #42 out of 100 companies for Net Current Asset Value. This puts Scope Fluidics Spolka Akcyjna in the upper half of its industry. The industry median Net Current Asset Value is 4.03. Historically, Scope Fluidics Spolka Akcyjna's own Net Current Asset Value has ranged from 1.52 to 181.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Diagnostics & Research company?
The median Net Current Asset Value among Medical Diagnostics & Research companies is 4.03, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. For the Medical Diagnostics & Research industry, the median Net Current Asset Value is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scope Fluidics Spolka Akcyjna's current Net Current Asset Value is zł37.22, which is 516% above median its own 10-year median of 6.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna (WAR:SCP) is currently considered Fairly Valued. The stock's GF Value™ is zł129.17, compared to a current price of zł122.00 — trading 5.6% below its estimated fair value. The current Net Current Asset Value is zł37.22, which is 516% above median its 10-year median of 6.04. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (WAR:SCP), the current Net Current Asset Value is zł37.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scope Fluidics Spolka Akcyjna (WAR:SCP) Overvalued in 2026?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be undervalued.
The current stock price of zł122.00 is trading 5.6% below its estimated GF Value™ of zł129.17.
GuruFocus considers Scope Fluidics Spolka Akcyjna to be Fairly Valued.
Key valuation signals for WAR:SCP:
Net Current Asset Value: zł37.22 (516% above median its 10-year median of 6.04)
GF Value™: zł129.17 vs. price of zł122.00 (5.6% below fair value)
No single metric tells the full story. See the WAR:SCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scope Fluidics Spolka Akcyjna Business Description
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
50GF Score
Get the complete analysis for WAR:SCP
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCP has been successfully added to your 
